Aisha Khanum, Vinay Pandit, Shyamala Bhaskaran, Vasiha Banu
Aisha Khanum*, Vinay Pandit, Shyamala Bhaskaran and Vasiha Banu
Al-Ameen College of Pharmacy, Hosur Road, Bangalore, India
Volume - 1,
Issue - 4,
Year - 2008
Overactive bladder is a chronic, and distressing medical condition characterized by urinary urgency and frequency, with or without urge incontinence, that often requires long term treatment to maintain control of symptoms. Tolterodine tartarate is an anticholinergic drug used to treat overactive bladder. The suitability of drug with respect to lower dose, solubility, lower molecular weight and short half-life makes this drug as a suitable candidate for administration by transdermal route. A number of polymers such as HPMC, Carbopol-934P, and Ethyl cellulose were employed alone and in combination for the preparation of transdermal films. The films were casted using solvent casting technique. Solutions containing polymer at different concentrations (2%, 3%, 4%, w/w) and a plasticizer (propylene glycol) at various concentrations (20%, 30%, 40%, w/w) were prepared. These solutions were then used to prepare films. Prepared films were then evaluated for various physicochemical properties like physical appearance, weight variation, thickness, drug content, folding endurance and percentage elongation, including in-vitro release study. Among the various polymers examined result show’s that the combination of HPMC: carbopol-934P (3:1) with 30% propylene glycol (PG), films formed were very flexible, with high folding endurance and uniform drug content. Further permeation study showed 68.72% and 81.12% release across the rat abdominal skin and cellophane membrane respectively for 12 hours. Thus it may be concluded that transdermal films are a promising drug delivery system for Tolterodine tartarate with more patient compliance in the treatment of overactive bladder.
Cite this article:
Aisha Khanum, Vinay Pandit, Shyamala Bhaskaran, Vasiha Banu. Preparation and Evaluation of Tolterodine Tartarate Transdermal Films for the Treatment of Overactive Bladder. Research J. Pharm. and Tech. 1(4): Oct.-Dec. 2008;Page 516-521.